597 related articles for article (PubMed ID: 31580544)
1. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
[TBL] [Abstract][Full Text] [Related]
3. Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
Volterrani M; Perrone V; Sangiorgi D; Giacomini E; Iellamo F; Degli Esposti L;
Eur J Heart Fail; 2020 Nov; 22(11):2049-2055. PubMed ID: 33459467
[TBL] [Abstract][Full Text] [Related]
4. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
[TBL] [Abstract][Full Text] [Related]
6. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease.
Santoro A; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Degli Esposti L
J Nephrol; 2022 Mar; 35(2):463-472. PubMed ID: 34115311
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.
Kanda E; Rastogi A; Murohara T; Lesén E; Agiro A; Arnold M; Chen G; Yajima T; Järbrink K; Pollack CV
BMC Nephrol; 2023 Jan; 24(1):18. PubMed ID: 36658531
[TBL] [Abstract][Full Text] [Related]
8. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
[TBL] [Abstract][Full Text] [Related]
9. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
[TBL] [Abstract][Full Text] [Related]
10. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
[TBL] [Abstract][Full Text] [Related]
11. Optimally managing hyperkalemia in patients with cardiorenal syndrome.
Wang AY
Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii36-iii44. PubMed ID: 31800079
[TBL] [Abstract][Full Text] [Related]
12. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.
Evans M; Palaka E; Furuland H; Bennett H; Linde C; Qin L; McEwan P; Bakhai A
BMC Nephrol; 2019 Jan; 20(1):31. PubMed ID: 30704421
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
[TBL] [Abstract][Full Text] [Related]
14. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
[TBL] [Abstract][Full Text] [Related]
15. Hyperkalemia in the Hypertensive Patient.
Lakkis JI; Weir MR
Curr Cardiol Rep; 2018 Mar; 20(2):12. PubMed ID: 29492706
[TBL] [Abstract][Full Text] [Related]
16. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
Pitt B; Garza D
Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28485202
[TBL] [Abstract][Full Text] [Related]
18. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
[TBL] [Abstract][Full Text] [Related]
19. Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.
Paolillo S; Basile C; Dell'Aversana S; Esposito I; Chirico A; Colella A; Esposito G; Santo MD; Fierro MF; Carbone F; Marzano F; Amato C; Gargiulo P; Perrone Filardi P
Eur J Intern Med; 2024 Jan; 119():109-117. PubMed ID: 37648583
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
